Trial Profile

A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Otlertuzumab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Emergent BioSolutions; Emergent Product Development Gaithersburg

Most Recent Events

16 Dec 2016 Primary endpoint has been met. (Overall response rate (ORR)), as reported by an Aptevo Therapeutics media release.
16 Dec 2016 The results from Phase II portion were published in the British Journal of Haematology (BJH) 2016, as reported by an Aptevo Therapeutics media release.
16 Dec 2016 Results from Phase II portion published in an Aptevo Therapeutics Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com